Cargando…

Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAF(V600E)-driven human cancers

The activating TERT promoter mutations and BRAF(V600E) mutation are well-established oncogenic alterations in human cancers. Coexistence of BRAF(V600E) and TERT promoter mutations is frequently found in multiple cancer types, and is strongly associated with poor patient prognosis. Although the BRAF(...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Yongxing, Shi, Liang, Zhao, Yuelei, Chen, Pu, Cui, Rongrong, Ji, Meiju, He, Nongyue, Wang, Maode, Li, Gang, Hou, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822828/ https://www.ncbi.nlm.nih.gov/pubmed/33483600 http://dx.doi.org/10.1038/s41698-020-00140-5

Ejemplares similares

CYP2S1 is a synthetic lethal target in BRAF(V600E)-driven thyroid cancers
por: Li, Yiqi, et al.
Publicado: (2020)

TERT and its binding protein: overexpression of GABPA/B in high grade gliomas
por: Papazacharias, Efthymios, et al.
Publicado: (2021)

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF(V600E)/TERT promoter double-mutated glioma
por: Gabler, Lisa, et al.
Publicado: (2019)

Mechanisms of TERT Reactivation and Its Interaction with BRAF(V600E)
por: Song, Young Shin, et al.
Publicado: (2020)

Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer
por: Liu, Rengyun, et al.
Publicado: (2018)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Disulfiram/Cu Kills and Sensitizes BRAF-Mutant Thyroid Cancer Cells to BRAF Kinase Inhibitor by ROS-Dependently Relieving Feedback Activation of MAPK/ERK and PI3K/AKT Pathways
por: Xie, Jingyi, et al.
Publicado: (2023)

TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas
por: Gao, Ke, et al.
Publicado: (2015)

c-Myc is Required for BRAF(V600E)-Induced Epigenetic Silencing by H3K27me3 in Tumorigenesis
por: Qu, Yiping, et al.
Publicado: (2017)

BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients
por: Sun, Jian, et al.
Publicado: (2016)

BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study
por: Kaley, Thomas, et al.
Publicado: (2018)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

BRAF(non-V600E) more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAF(V600E) but without a survival advantage
por: Wang, Wei, et al.
Publicado: (2021)

GABPA predicts prognosis and inhibits metastasis of hepatocellular carcinoma
por: Zhang, Sheng, et al.
Publicado: (2017)

GABPA Expression in Endometrial Carcinoma: A Prognostic Marker
por: Ma, Xiaoxue, et al.
Publicado: (2021)

Targeted Disruption of V600E-Mutant BRAF Gene by CRISPR-Cpf1
por: Yang, Meijia, et al.
Publicado: (2017)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
por: Peker, Yasar Subutay, et al.
Publicado: (2018)

STAG2 inactivation reprograms glutamine metabolism of BRAF-mutant thyroid cancer cells
por: Li, Xinru, et al.
Publicado: (2023)

An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer
por: Xue, Yaohua, et al.
Publicado: (2017)

Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma
por: Nepote, Alessandro, et al.
Publicado: (2022)

Induction of Resistance to BRAF Inhibitor Is Associated with the Inability of Spry2 to Inhibit BRAF-V600E Activity in BRAF Mutant Cells
por: Ahn, Jun-Ho, et al.
Publicado: (2015)

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
por: Xu, Ting, et al.
Publicado: (2022)

The Evolutionary Landscape of Treatment for BRAF(V600E) Mutant Metastatic Colorectal Cancer
por: Mauri, Gianluca, et al.
Publicado: (2021)

TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in Korea
por: Kim, Min Jhi, et al.
Publicado: (2022)

GABPA-dependent down-regulation of DICER1 in follicular thyroid tumours
por: Paulsson, Johan O, et al.
Publicado: (2020)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
por: Robinson, Giles W, et al.
Publicado: (2014)

Dual inhibition of BRAF and mTOR in BRAF(V600E)-mutant pediatric, adolescent, and young adult brain tumors
por: Sen, Shiraj, et al.
Publicado: (2020)

Contemporary treatment approaches for metastatic colorectal cancer driven by BRAF V600 mutations
por: Kanat, Ozkan, et al.
Publicado: (2020)

BRAF (AMP) Frequently Co-occurs With IDH1/2, TP53, and ATRX Mutations in Adult Patients With Gliomas and Is Associated With Poorer Survival Than That of Patients Harboring BRAF (V600E)
por: Da, Rong, et al.
Publicado: (2021)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China
por: Huang, Meiling, et al.
Publicado: (2019)

Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans
por: Kim, Sue Youn, et al.
Publicado: (2020)

How do BRAF(V600E) and TERT promoter mutations interact with the ATA and TNM staging systems in thyroid cancer?
por: Mukhtar, Noha, et al.
Publicado: (2023)

Preoperative detection of TERT promoter and BRAF(V600E) mutations in papillary thyroid carcinoma in high-risk thyroid nodules
por: Giorgenon, Tatiana Marina Vieira, et al.
Publicado: (2019)

HGG-02. ADOLESCENT AND YOUNG ADULT (AYA) GLIOMA WITH BRAF V600E-MUTANTATION
por: Kimura, Yui, et al.
Publicado: (2020)

BRAF(V600E) Mutant Allele Frequency (MAF) Influences Melanoma Clinicopathologic Characteristics
por: Soria, Xavier, et al.
Publicado: (2021)

Clinical significance of immunohistochemistry to detect BRAF V600E mutant protein in thyroid tissues
por: Zhang, Yini, et al.
Publicado: (2021)

Vemurafenib for BRAF V600‐mutant Erdheim–Chester disease presenting with bilateral orbital involvement
por: Wang, Xiaomeng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p8b4vnokg7ap1bq64vgkm9r9i2